NASDAQ:CTSO Cytosorbents (CTSO) Stock Price, News & Analysis $0.38 +0.00 (+1.29%) As of 12:50 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Cytosorbents Stock (NASDAQ:CTSO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cytosorbents alerts:Sign Up Key Stats Today's Range$0.38▼$0.4050-Day Range$0.36▼$0.5952-Week Range$0.35▼$1.22Volume16,276 shsAverage Volume116,872 shsMarket Capitalization$24.19 millionP/E RatioN/ADividend YieldN/APrice Target$5.38Consensus RatingHold Company Overview Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure. CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America. In the United States, the device received Emergency Use Authorization from the U.S. Food and Drug Administration for treatment of critically ill COVID-19 patients exhibiting a cytokine storm. Clinicians integrate CytoSorb into standard extracorporeal circuits such as continuous renal replacement therapy (CRRT) and cardiopulmonary bypass to optimize blood purification protocols in intensive care units. Beyond its core sorbent technology, Cytosorbents is advancing a pipeline of next-generation products aimed at drug overdose management and vaccine adjuvant development. The company’s R&D efforts leverage proprietary polymer bead platforms to broaden the applications of hemoadsorption in pharmaceutical safety and immunotherapy. With a global sales and distribution network and strategic partnerships in key markets, Cytosorbents continues to expand clinical evidence to support broader adoption of its blood purification solutions.AI Generated. May Contain Errors. Read More Cytosorbents Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreCTSO MarketRank™: Cytosorbents scored higher than 52% of companies evaluated by MarketBeat, and ranked 445th out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCytosorbents has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialCytosorbents has a consensus price target of $5.38, representing about 1,281.7% upside from its current price of $0.39.Amount of Analyst CoverageCytosorbents has only been the subject of 1 research reports in the past 90 days.Read more about Cytosorbents' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.19) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cytosorbents' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.59% of the float of Cytosorbents has been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 6.23.Change versus previous monthShort interest in Cytosorbents has recently decreased by 0.41%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Cytosorbents this week, compared to 2 articles on an average week.Search Interest5 people have searched for CTSO on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership3.5 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $104,898.00 in company stock, which represents 0.4291% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have bought more of their company's stock than they have sold. Specifically, they have bought $104,898.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders7.80% of the stock of Cytosorbents is held by insiders.Percentage Held by Institutions32.87% of the stock of Cytosorbents is held by institutions.Read more about Cytosorbents' insider trading history. Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTSO Stock News HeadlinesCytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business HighlightsJuly 20 at 7:00 AM | prnewswire.comCytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026June 18, 2026 | globenewswire.comSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.July 21 at 1:00 AM | Weiss Ratings (Ad)Cytosorbents Corp.June 17, 2026 | marketwatch.comCytosorbents (CTSO) Q1 2026 Earnings TranscriptJune 2, 2026 | finance.yahoo.comCTSO: CytoSorbents Reports 1st Quarter Financial and Operating ResultsMay 22, 2026 | finance.yahoo.comTranscript: CytoSorbents Q1 2026 Earnings Conference CallMay 15, 2026 | finance.yahoo.comCytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...May 14, 2026 | uk.finance.yahoo.comSee More Headlines CTSO Stock Analysis - Frequently Asked Questions How have CTSO shares performed this year? Cytosorbents' stock was trading at $0.6392 at the beginning of 2026. Since then, CTSO shares have decreased by 39.1% and is now trading at $0.3890. How were Cytosorbents' earnings last quarter? Cytosorbents Corporation (NASDAQ:CTSO) announced its earnings results on Wednesday, May, 13th. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.02. The medical research company earned $8.86 million during the quarter, compared to analyst estimates of $9.40 million. Cytosorbents had a negative trailing twelve-month return on equity of 235.57% and a negative net margin of 31.85%. Read the conference call transcript. How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Corning (GLW), UnitedHealth Group (UNH) and Docusign (DOCU). Company Calendar Last Earnings5/13/2026Today7/21/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 CTSO's financial health is in the Red zone, according to TradeSmith. CTSO has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:CTSO CIK1175151 Webwww.cytosorbents.com Phone(732) 329-8885Fax732-329-8650Employees220Year Founded2002Price Target and Rating Average Price Target for Cytosorbents$5.38 High Price Target$10.00 Low Price Target$0.75 Potential Upside/Downside+1,296.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.20 million Net Margins-31.85% Pretax Margin-32.93% Return on Equity-235.57% Return on Assets-37.88% Debt Debt-to-Equity Ratio4.70 Current Ratio1.09 Quick Ratio0.81 Sales & Book Value Annual Sales$37.06 million Price / Sales0.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book4.28Miscellaneous Outstanding Shares62,840,000Free Float57,941,000Market Cap$24.19 million OptionableOptionable Beta1.39 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CTSO) was last updated on 7/21/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytosorbents With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
